Institutions / Eversept Partners, LP

Eversept Partners, LP

CIK 1697013 · Institution · as of Dec 31, 2025
Portfolio value
$1.78B
Positions
103
As of
Dec 31, 2025

Top holdings

Dec 31, 2025View all 103 →
CompanyClassValueShares% of portfolio
Vera Therapeutics, Inc.$155.58M3,072,3048.7%
Gsk PLC$131.41M2,679,7217.4%
United Therapeutics Corp$123.08M252,5926.9%
Abivax SA$88.71M657,8345.0%
Natera, Inc.$76.63M334,4934.3%
Syndax Pharmaceuticals Inc$69.64M3,314,4083.9%
Viridian Therapeutics, Inc.$55.46M1,782,2353.1%
Vaxcyte, Inc.$55.26M1,197,7223.1%
Travere Therapeutics, Inc.$44.90M1,174,9682.5%
HCA Healthcare, Inc.$44.76M95,8742.5%
Danaher Corp /De$42.64M186,2622.4%
Ionis Pharmaceuticals Inc$42.58M538,2182.4%
Celldex Therapeutics, Inc.$38.97M1,434,7252.2%
Bruker Corp$36.92M783,7892.1%
Avantor, Inc.$36.40M3,176,6442.0%
Community Health Systems Inc$24.78M7,943,8021.4%
Exact Sciences Corp.$24.54M241,6781.4%
Biocryst Pharmaceuticals Inc$23.34M2,992,8951.3%
Geron Corp$23.31M17,659,9831.3%
BIO-TECHNE Corp$22.20M377,4051.2%
Cidara Therapeutics Inc$21.81M98,7211.2%
Insulet Corp$21.24M74,7081.2%
Beta Bionics, Inc.$20.67M678,2621.2%
Teva Pharmaceutical Industries LtdTEVAADR$20.60M660,1771.2%
Unitedhealth Group Inc$20.09M60,8621.1%

Activity

Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.